Remtolumab

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameRemtolumab

Drug Alias NameABT-122D2E7-GS10-B6-17

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionTumor necrosis factor α inhibitorsInterleukin-17 inhibitors

TargetsInterleukin-17Tumor necrosis factor α

Therapy Area/IndicationsArthritis, RheumatoidArthritis, Psoriatic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBulgariaUnited States +[11]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAbbvie Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAbbvie Inc

Active IndicationsN/A

Inactive IndicationsArthritis, RheumatoidArthritis, Psoriatic

Other Information

ATC CodeN/A